
CLAIMS


1. A compound of formula (I), or a pharmaceutically acceptable salt thereof,








(I)

wherein

n is 2-20;


Q^1 is a bond or , wherein m is 0-100;



L is , , , , or , wherein R^x is H or halogen;



Q^2 is a bond or a self-immolative spacer; and



Z is a polo-like kinase 1 (PLK-1) inhibitor, a tubulin polymerase inhibitor, a tubulin stabilizer, an antineoplastic agent, an eukaryotic translation initiation factor 4 (EIF4) inhibitor, or a combretastatin A-4 analog.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein


Q^1 is a bond or ;



L-Q^2 is  ,  ,


 ,  ,

 , or  .

3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein

Q^1 is ;

L-Q^2 is  ,  , or


 ; and




Z is a PLK-1 inhibitor, a tubulin polymerase inhibitor, a tubulin stabilizer, an antineoplastic agent, or an eukaryotic translation initiation factor 4 (EIF4) inhibitor.

4. The compound of claim 3, wherein Z is a PLK-1 inhibitor or an antineoplastic agent selected from the group consisting of monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), and monomethyl auristatin E (MMAD).

5. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein


n is 18;

Q^1 is ;


L-Q^2 is , , or ; and

Z is a combretastatin A-4 analog.


6. The compound of claim 1, which is selected from the group consisting of




(CLR2208),




(CLR2206),







(CLR2200),



(CLR2013),



(CLR2000045), and



(CLR2010),

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. Use of an effective amount of a compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a subject in need thereof.

9. The use of claim 8, wherein the cancer is melanoma, lung cancer, colorectal cancer, breast cancer, or a combination thereof.

10. The use of claim 9, wherein

the lung cancer comprises small cell lung cancer, non-small cell lung cancer, or a combination thereof;

the melanoma comprises superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, nevoid melanoma, spitzoid melanoma, desmoplastic melanoma, or a combination thereof;

the colorectal cancer comprises adenocarcinoma; or


the breast cancer comprises invasive breast ductal carcinoma, metastatic breast cancer, inflammatory breast cancer, triple negative breast cancer, ductal carcinoma in situ, or a combination thereof.



11. The use of any one of claims 8-10, wherein the cancer comprises cancer stem cells.


12. The use of any one of claims 8-11, wherein the cancer comprises metastatic cancer cells.

13. The use of any one of claims 8-12, wherein the cancer comprises circulating tumor cells.

14. The use of any one of claims 8-13, wherein the cancer is melanoma, lung cancer, colorectal cancer, or a combination thereof, and wherein

Q^1 is ;

L-Q^2 is , , or


; and



Z is a PLK-1 inhibitor, a tubulin polymerase inhibitor, a tubulin stabilizer, an antineoplastic agent, or an eukaryotic translation initiation factor 4 (EIF4) inhibitor.


15. The use of any one of claims 8-13, wherein the cancer is breast cancer, wherein the subject (1) is estrogen receptor positive, (2) is both estrogen receptor negative and progesterone receptor negative, (3) expresses HER2 (HER2+), (4) does not express HER2 (HER2−), or a combination thereof.

16. The use of any one of claims 8-13 and 15, wherein the cancer is breast cancer, and wherein

n is 18;

Q^1 is ;

$L\text{-}Q^2$ is , , or

; and

Z is a combretastatin A-4 analog.